|Strategy:||Combo: Protein & vector vaccines|
|Study Type:||Phase IIb|
|Stage:||Follow-up (closed to accrual)|
|Study Start Date:||2017-10-31|
|Study Made Public:||NA|
A multicenter, randomized, double-blind, placebo-controlled Phase 2b efficacy study of a heterologous prime/boost vaccine regimen of Ad26.Mos4.HIV and aluminum phosphate-adjuvanted Clade C gp140 in preventing HIV-1 infection in women in sub-Saharan Africa
HVTN 705/HPX2008 (Imbokodo) is a Phase IIb clinical trial evaluate the safety and immunogenicity of Ad26.Mos4.HIV (Ad26) and Clade C gp140.
Sign in to see full information about this study and to download study data.
ProductsProduct info coming soon!
No integrated data is available for this study.
No non-integrated data is available for this study.